Latest Innovation News

Lithium Universe Limited has taken a significant step forward in its North American lithium refining ambitions by confirming the suitability of a Brownsville, Texas site for its second refinery. This move supports a binational platform designed to meet surging demand for battery-grade lithium carbonate.

Pilot Energy has secured a $10.75 million joint development agreement with SN Energy to build a hybrid solar and battery storage project alongside a proposed 50MW data centre at Three Springs.

Adisyn Ltd has successfully demonstrated low-temperature deposition of an sp²-based carbon layer using Atomic Layer Deposition, a milestone independently verified and critical for semiconductor integration.

VBX Limited reports promising exploration drilling results from its Wuudagu E and F bauxite plateaus, revealing thicker deposits with higher alumina and lower silica content than previously recorded. These findings could significantly expand the company’s resource base in northern Western Australia.

Nexsen Limited has initiated FDA engagement for its rapid Group B Streptococcus diagnostic sensor, aiming for expedited US market entry, while bolstering its leadership team and scientific credentials.

Metallium’s US subsidiary has locked in a binding multi-year supply agreement with Glencore for electronic scrap, underpinning the commercial scale-up of its innovative Flash Joule Heating technology in Texas.

Temas Resources has fortified its position in the critical minerals sector through key strategic moves including joining Québec’s CSM Scientific Network, engaging market-making services, and commissioning independent equity research.

BlinkLab Limited has secured independent scientific validation for its smartphone-based autism diagnostic technology through publication in the prestigious journal Autism Research, marking a significant milestone ahead of its FDA regulatory trial.

Biome Australia Limited has reported a record-breaking quarter and half-year sales performance, driven by strong demand for its clinically-backed probiotic products. Revenue surged over 40% compared to the previous year, defying typical seasonal slowdowns.

AdAlta Limited and its subsidiary AdCella have partnered with Shanghai Cell Therapy Group to co-develop a pioneering CAR-T cancer therapy targeting solid tumours outside China. This collaboration aims to bring a novel, armored immunotherapy with promising clinical results to global markets.

Neurizon Therapeutics has progressed its ALS treatment NUZ-001 into critical clinical trial phases, even as the FDA declines its Fast Track Designation request pending more data.

Arovella Therapeutics has taken a significant step forward by submitting an IND application to the U.S. FDA for its lead CAR-iNKT cell therapy, ALA-101, targeting blood cancers. This milestone paves the way for a first-in-human Phase 1 trial in both Australia and the U.S.